NCT05277129Recruiting
The Immune Response to Stroke
Source: ClinicalTrials.gov · Last updated 14 Mar 2022 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Some patients develop cognitive decline after a stroke, but we don't always understand the mechanisms. It has been proposed that a proportion of the patients develop an autoimmune immune response, and that this could potentially explain the cognitive decline in some of the patients. The current study aims to investigate this hypothesis in a subgroup of patients with stroke.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 40 (estimated)
- First submitted
- 3 Mar 2022
- Start date
- Jun 2021
- Primary completion date
- Dec 2025
- Lead sponsor
- University of Oslo
- Diseases
- Stroke
- NCT number
- NCT05277129
What you commit to
- Study type: Observational
- Planned participants: 40
- From Jun 2021 to the primary completion date, Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous or present immunological disease or other serious comorbidity
Other illness
- Brain hemorrhage verified by CT or MRI scan
- Ongoing immune respons after infection or vaccination \< 1 month
Other
- Cognitive without ability to understand and/or give an informed consent to participate in the study
Who the study is looking for
- Stroke \< 72 h
- Age \> 18 years
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Akershus University Hospital Coordinator of this site? Confirm its status | Lørenskog | Norway | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.